Business
ENDRA Life Sciences Announces New Clinical Study Partnership with the Centre Hospitalier Universitaire d'Angers, France
Study to Bolster Clinical Evidence of Performance of Patented TAEUS Ultrasound Device in NAFLD Patients as Commercialization BeginsANN ARBOR, MI / ACCESSWIRE
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"Study to Bolster Clinical Evidence of Performance of Patented TAEUS Ultrasound Device in NAFLD Patients as Commercialization BeginsANN ARBOR, MI / ACCESSWIRE / December 3, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that Centre Hospitalier Universitaire d'Angers, France (CHU Angers), a world-renowned healthcare institution, is partnering with ENDRA for a clinical study of ENDRA's Thermo Acoustic Enhanced UltraSound (TAEUS™) device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD).\"We are thrilled that CHU Angers, a renowned French clinical and teaching institution, is evaluating TAEUS as a tool to characterize NAFLD, a condition that impacts more than 1 billion people globally,\" said ENDRA Life Sciences Chief Commercial Officer Renaud Maloberti. \"It's an honor for ENDRA to garner the clinical interest of this leading research institution. We look forward to building our relationship with CHU Angers as we begin commercializing TAEUS in Europe.\"This is the second clinical research partnership for ENDRA in Europe and the fifth globally. It is a natural progression from the feasibility study conducted by the Robarts Research Institute in Canada, and the first evaluation site that was deployed earlier this month at Rocky Vista University in the United States. The data from the CHU Angers study, along with other ongoing or to-be-initiated studies, will be used to bolster the clinical evidence and further establish the clinical utility of the TAEUS ultrasound device in patients with NAFLD, as commercialization begins. The study will be led by Pr. Christophe Aube, MD, PUPH, Chair of the Radiology department in close association with Pr. Jerome Boursier, MD, PUPH, Chair of the Hepatology department.\"NAFLD and NASH are rapidly rising among the population and the options to assess and monitor liver fat in NAFLD patients, namely MRI and liver biopsy, are difficult to integrate into routine clinical practice. Clinicians need to have access to more practical tools to help manage patients with this chronic condition,\" said Pr. Aube. \"We are looking forward to conducting this evaluation of TAEUS in our patients with NAFLD, and to better understanding the potential clinical utility of ENDRA's TAEUS technology as it compares to MRI,\" added Pr. Boursier.The goa...